FDA Seeks Advice on Patient Data Behind Real-World Drug Evidence
Published Date: 11/12/2026
Notice
Summary
The FDA wants your ideas on how to handle patient-level data when using real-world evidence for drug and biological product approvals. This affects drug makers, tech vendors, researchers, and patient groups who submit or use this data. Comments are open until January 11, 2027, so jump in now to help shape smarter, smoother data rules that could speed up approvals and improve health outcomes.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 3 costs, 1 mixed.
Sponsors must ensure patient-level RWD submission
If you are a drug or biologics sponsor, you must be able to submit patient-level real-world data (RWD) for any real-world evidence (RWE) used in clinical studies when required under 21 CFR 314.50 and 21 CFR 601.2. If you do not own the RWD, you should establish agreements with the data owners so the relevant patient-level data and source records can be provided to FDA and made available for inspection.
FDA cannot accept data-use terms that conflict with law
FDA states it often cannot sign data-use agreements (DUAs) that include terms conflicting with its legal obligations. Examples given include DUA terms requiring data destruction that conflict with federal recordkeeping, ownership or access terms that conflict with preserving administrative records, and sharing limits that conflict with the Freedom of Information Act (FOIA).
No acceptance of external database links; DMF/pre-IND routes available
FDA does not accept links to external databases for patient-level RWD submissions. The notice explains third-party data providers may instead provide data to FDA by opening a pre-IND or a Type V drug master file (DMF), with the sponsor providing a letter of authorization to allow FDA to reference that data.
Large, complex RWD create technical submission challenges
FDA notes real-world datasets (for example, longitudinal records, imaging, or multi-omics) are often substantially larger than typical clinical trial datasets, and that submission via traditional channels can be difficult. This creates technical challenges for data transfer, storage, and processing within FDA's existing infrastructure.
Stakeholders can comment by January 11, 2027
FDA is requesting public comments on patient-level data access for RWD/RWE and will accept electronic or written comments until January 11, 2027 (electronic filing accepted until 11:59 p.m. Eastern Time on that date). Interested parties named include regulated industry, health information technology vendors, academic medical centers, electronic data capture vendors, and patient advocates.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22995, Notice of Inventory Completion: Auburn University at Montgomery, Montgomery, AL
Auburn University at Montgomery has finished checking its collection and found 11 Native American human remains and 75 related objects from Alabama. These items are ready to be returned to the right Native tribes starting December 14, 2026. If you represent a tribe or group, you can ask for these remains and objects by contacting the university.
Next: 2026-22998, Notice of Inventory Completion: William S. Webb Museum of Anthropology, University of Kentucky, Lexington, KY
The William S. Webb Museum of Anthropology at the University of Kentucky has finished checking its collection and found Native American human remains and related items that belong to certain tribes. Starting December 14, 2026, these remains and objects can be returned to the tribes. This is a respectful step to honor Native American heritage with no costs or hazards involved.